•  
  •  
 

Turkish Journal of Chemistry

Abstract

Based on the privileged fragment-based drug design strategy, a series of imatinib analogues bearing the moiety of 3-(2-amino- 2-oxoacetyl)-1H-indole were designed and synthesized, and the in vitro antitumor activity of these compounds was detected by MTT method using K562 (human myeloid leukemia) and K562R (imatinib-resistant chronic myeloid leukemia) cell lines. Molecular docking was used to preliminarily explain the possible binding modes. The most potent compound I2 exhibited better antitumor activity than those of imatinib against K562 and K562R cancer cells with IC50 values of 0.8 ?M and 0.7 ?M.

DOI

10.55730/1300-0527.3549

Keywords

Privileged fragment-based drug design, imatinib, antitumor; synthesis

First Page

426

Last Page

435

Included in

Chemistry Commons

Share

COinS